Translational Development Acquisition Corp. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Michael B. Hoffman (CEO) and Avanindra C. Das (CFO) issued standard Sarbanes-Oxley certifications on August 14, 2026 for the Q2 2026 10-Q filing. Both officers certified that the report contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are designed and operating effectively. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certifications; no operational, financial, or strategic substance disclosed. Boilerplate compliance filing.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.